Comt Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The COMT (Catechol-O-Methyltransferase) gene encodes an enzyme that degrades catecholamines including dopamine, epinephrine, and norepinephrine. COMT activity in the prefrontal cortex regulates dopamine levels and cognitive function. A common functional polymorphism (Val158Met) affects enzyme activity and is associated with psychiatric disorders. [1]
This gene is involved in: [2]
COMT encodes catechol-O-methyltransferase, a key enzyme in the metabolism of catecholamines including dopamine, norepinephrine, and epinephrine. COMT plays critical roles in dopaminergic signaling, executive function, and pain perception. [3]
| Attribute | Value | [4]
|-----------|-------| [5]
| Gene Symbol | COMT |
| Full Name | Catechol-O-Methyltransferase |
| Chromosome | 22 |
| Genomic Location | 22q11.21 |
| OMIM | 116790 |
| Ensembl ID | ENSG00000093072 |
| UniProt ID | P21964 |
The COMT gene encodes catechol-O-methyltransferase, an enzyme that catalyzes the methylation of catecholamines using S-adenosylmethionine (SAM) as a methyl donor. COMT is essential for dopamine catabolism in the prefrontal cortex.
COMT is central to Parkinson's disease treatment:
COMT catalyzes the methylation of dopamine to produce 3-methoxytyramine (3-MT), which is subsequently metabolized to homovanillic acid (HVA). This pathway is the primary mechanism for dopamine clearance in the prefrontal cortex.
COMT also methylates epinephrine and norepinephrine, contributing to the regulation of sympathetic tone and stress responses.
| Drug | Type | Clinical Use | Notes |
|---|---|---|---|
| Entacapone | Selective, peripheral | PD adjunct | Once-daily dosing |
| Tolcapone | Non-selective, central | PD adjunct | Requires liver monitoring |
| Opicapone | Selective, peripheral | PD adjunct | Once-daily, long-lasting |
The study of Comt Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
PMID: 16380913] Tunbridge EM, Harrison PJ, Weinberger DR. Catechol-o-methyltransferase, cognition, and psychosis. Mol Psychiatry. 2006. ↩︎
PMID: 17412775] Yacubian J, Sommer T, Schroeder K, et al. Gene-gene interaction associated with neural reward sensitivity. Proc Natl Acad Sci USA. 2007. ↩︎
PMID: 12629556] Mannisto PT, Kaakkola S. Catechol-O-methyltransferase (COMT): Biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev. 1999. ↩︎
PMID: 19141701] Axelstad M, Bossi R, Vinggaard AM, et al. COMT genotype and brain function. Neurotoxicology. 2008. ↩︎
PMID: 21207076] Wu J, Xiao H, Sun H, et al. Role of dopamine receptors in Parkinson's disease. CNS Drugs. 2012. ↩︎